Cargando…

Biomarkers for Microglial Activation in Alzheimer's Disease

Intensive research over the last decades has provided increasing evidence for neuroinflammation as an integral part in the pathogenesis of neurodegenerative diseases such as Alzheimer's disease (AD). Inflammatory responses in the central nervous system (CNS) are initiated by activated microglia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lautner, Ronald, Mattsson, Niklas, Schöll, Michael, Augutis, Kristin, Blennow, Kaj, Olsson, Bob, Zetterberg, Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206374/ https://www.ncbi.nlm.nih.gov/pubmed/22114747 http://dx.doi.org/10.4061/2011/939426

Ejemplares similares

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer’s Disease
por: Armstrong, Andrea, et al.
Publicado: (2013)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
por: Pereira, Joana B., et al.
Publicado: (2022)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
por: Pikwer, Andreas, et al.
Publicado: (2017)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
por: Lautner, Ronald, et al.
Publicado: (2017)

Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy
por: Grothe, Michel J., et al.
Publicado: (2021)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease
por: Johansson, Per, et al.
Publicado: (2013)

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
por: Simrén, Joel, et al.
Publicado: (2021)

Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
por: Parbo, Peter, et al.
Publicado: (2020)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lhv4orkfgdc6ht68kkvkq1rpct